ClinicalTrials.gg

Program

eptinezumab

Also written as “Eptinezumab”, “ALD403” and “ALD403 (Eptinezumab)”.

Its studies are mostly in Migraine Disorders · Cluster Headache, led by 2 companies.

Furthest: phase 4, since Feb 23, 202223 company-led studies, 4 open or runningNext primary completion: Mar 26, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
H. Lundbeck223 open or runningphase 4since Feb 23, 2022Apr 16, 2012Mar 26, 2027phase 3 · NCT04965675
Dr George Medvedev11 open or runningphase 3since May 16, 2024May 16, 2024Mar 2028phase 3 · NCT06428838

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 9 studies since Apr 16, 2012.

  1. Aug 28, 2020Phase 1 study in Migraine DisordersH. Lundbeck · NCT04537429 · 28 enrolled · United States
  2. Dec 24, 2020Phase 3 study in Cluster HeadacheH. Lundbeck · NCT04688775 · 231 enrolled · United States, Belgium, Czechia and more
  3. Feb 23, 2021Phase 3 study in Migraine DisordersH. Lundbeck · NCT04772742 · 193 enrolled · China, Georgia, Korea, Republic of and more
  4. Jun 4, 2021Phase 3 study in Migraine DisordersH. Lundbeck · NCT04921384 · 981 enrolled · China, Georgia, Japan and more
  5. Jul 7, 2021Phase 3 study in Chronic Migraine in ChildrenH. Lundbeck · NCT04965675 · 285 planned · United States, Argentina, Canada and more
  6. Sep 7, 2021Phase 1 study in HealthyH. Lundbeck · NCT05045781 · 20 enrolled · China
  7. Sep 22, 20212 phase 3 studiesH. Lundbeck · NCT05064397, NCT05064371
  8. Dec 7, 2021Phase 3 study in Migraine DisordersH. Lundbeck · NCT05164172 · 600 planned · United States, Argentina, Canada and more
  9. Feb 23, 2022Phase 4 study in Migraine DisordersH. Lundbeck · NCT05284019 · 32 enrolled · United States
  10. Jul 6, 2022Phase 4 study in Migraine DisordersH. Lundbeck · NCT05452239 · 608 enrolled · United States, Australia, Denmark and more
  11. May 31, 2023Phase 3 study in Episodic MigraineH. Lundbeck · NCT05897320 · 315 planned · United States, Argentina, Canada and more
  12. May 16, 2024Dr George Medvedev's first study: phase 3 study in Migraine DisordersNew to Dr George MedvedevDr George Medvedev · NCT06428838 · 102 planned · Canada
  13. Nov 20, 2024Phase 4 study in Migraine DisordersH. Lundbeck · NCT06701526 · 164 enrolled · United States
  14. Oct 16, 2026Primary completion moved from 2026-09-05 to 2027-03-26Date moved laterphase 3 · +7 months · NCT04965675

Ahead

  1. Mar 26, 2027Primary completion: phase 3 study in Chronic Migraine in ChildrenH. Lundbeck · NCT04965675
  2. Jul 6, 2027Primary completion: phase 3 study in Episodic MigraineH. Lundbeck · NCT05897320
  3. Mar 2028Primary completion: phase 3 study in Migraine DisordersDr George Medvedev · NCT06428838
  4. Apr 30, 2028Primary completion: phase 3 study in Migraine DisordersH. Lundbeck · NCT05164172

TargetBeta

CALCA →CALCB →read by rule
“Calcitonin gene-related peptide inhibitor”ChEMBL 37, by rule

Studies

All 23 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06701526Migraine Disorders · United States4CompletedH. LundbeckSep 2, 2026164
NCT06428838Migraine Disorders · Canada3By invitationDr George MedvedevMar 2028102
NCT05897320Episodic Migraine · United States, Argentina, Canada and more3RecruitingH. LundbeckJul 6, 2027315
NCT05452239Migraine Disorders · United States, Australia, Denmark and more4CompletedH. LundbeckOct 22, 2024608
NCT05284019Migraine Disorders · United States4TerminatedH. LundbeckFeb 17, 202332
NCT05164172Migraine Disorders · United States, Argentina, Canada and more3RecruitingH. LundbeckApr 30, 2028600
NCT05064397Cluster Headache · United States, Denmark, Finland and more3CompletedH. LundbeckJun 29, 2023131
NCT05064371Migraine Disorders · Japan3CompletedH. LundbeckJun 8, 2024160
NCT05045781Healthy · China1CompletedH. LundbeckJul 20, 202120
NCT04965675Chronic Migraine in Children · United States, Argentina, Canada and more3RecruitingH. LundbeckMar 26, 2027285
NCT04921384Migraine Disorders · China, Georgia, Japan and more3CompletedH. LundbeckOct 1, 2024981
NCT04772742Migraine Disorders · China, Georgia, Korea, Republic of and more3CompletedH. LundbeckMay 23, 2022193
NCT04688775Cluster Headache · United States, Belgium, Czechia and more3CompletedH. LundbeckJun 14, 2023231
NCT04537429Migraine Disorders · United States1CompletedH. LundbeckOct 20, 202228
NCT04418765Migraine Disorders · United States, Belgium, Bulgaria and more3CompletedH. LundbeckJul 15, 2021892
NCT04336449Healthy · Japan1CompletedH. LundbeckAug 13, 202018
NCT04152083Migraine Disorders · United States, Georgia3CompletedH. LundbeckJul 8, 2020485
NCT02985398Migraine Disorders · United States3CompletedH. LundbeckApr 2018128
NCT02974153Migraine Disorders · United States, Belgium, Czechia and more3CompletedH. LundbeckNov 20171,121
NCT02559895Migraine Disorders · United States, Georgia3CompletedH. LundbeckFeb 2017898
NCT02275117Migraine Disorders · United States, Australia, Georgia and more2CompletedH. LundbeckMar 2016665
NCT01772524Migraine Disorders · United States1CompletedH. LundbeckDec 2013163
NCT01579383Migraine Disorders · Australia1CompletedH. LundbeckDec 2012104

How it is read

Names in the registry

  • “Eptinezumab”, 17 entries
  • “ALD403”, 5 entries
  • “ALD403 (Eptinezumab)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.